A similar randomized phase II trial of maintenance olaparib in resected pancreatic cancer and pathogenic BRCA1/BRCA2 or PALB2 mutations (ECOG-ACRIN EA2192, APOLLO) is enrolling patients with either germline or somatic mutations who have received 3 to 6 months of peri-operative chemotherapy. This evidence concerns the gene PALB2 and familial pancreatic carcinoma.